Our top pick for
Beginners

Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Immix Biopharma Inc is a biotechnology business based in the US. Immix shares (IMMX) are listed on the NASDAQ and all prices are listed in US Dollars. Immix employs 2 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
Latest market close | $2.60 |
---|---|
52-week range | $1.25 - $7.90 |
50-day moving average | $1.97 |
200-day moving average | $2.88 |
Wall St. target price | N/A |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-3.93 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.6 from 2022-07-01
1 week (2022-06-29) | 3.17% |
---|---|
1 month (2022-06-06) | 2.36% |
3 months (2022-04-06) | 28.08% |
6 months (2022-01-06) | -52.64% |
1 year (2021-07-02) | N/A |
---|---|
2 years (2020-07-02) | N/A |
3 years (2019-07-02) | N/A |
5 years (2017-07-02) | N/A |
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -15.46% |
Return on equity TTM | -331.05% |
Profit margin | 0% |
Book value | $1.42 |
Market capitalisation | $36.1 million |
TTM: trailing 12 months
We're not expecting Immix to pay a dividend over the next 12 months.
You may also wish to consider:
Immix Biopharma, Inc. , a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.